Human gut bacteria bioaccumulate per- and polyfluoroalkyl substances.
Anna E Lindell, Anne Grießhammer, Lena Michaelis...
https://pubmed.ncbi.nlm.nih.gov/40595288/Actively Recruiting
Led by Cambiotics ApS · Updated on 2026-10-08
70
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying the effects of a probiotic dietary supplement containing Streptococcus salivarius on serum levels of perfluoroalkyl substances PFAS in male firefighters who have been exposed to these chemicals through their work. This randomized, double-blind, placebo-controlled crossover pilot study aims to understand how the supplement influences PFAS elimination and related symptoms over two 12-week treatment periods separated by a washout phase. Participants will take either the probiotic supplement or a matching placebo capsule twice daily for 84 days, followed by a 28-day washout period, then switch to the other treatment for another 84 days. The study includes eight visits for blood sample collection, stool analysis, symptom questionnaires, and phone check-ins to assess changes in PFAS levels, gastrointestinal symptoms, and fatigue. During the study, participants will undergo serum PFAS measurements at baseline and after each intervention period. Researchers will also collect stool samples and use questionnaires to monitor gastrointestinal health and fatigue. The primary outcome is the change in serum linear perfluorooctane sulfonic acid n-PFOS levels. Safety, adherence, and symptom monitoring will continue throughout the approximately 28-week study duration.
CONDITIONS
Effect of a Dietary Supplement Versus Placebo on Serum PFAS Levels in Male Firefighters
A
Abigail O'Mahony, Operations Manager
S
Stacey Boetto, Princpal Investigator, DNP, FNP-C
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Cambiotics ApS
Lead Sponsor
Atlantia Food Clinical Trials
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Streptococcus salivarius 46-SL1 Probiotic | Placebo |
|---|---|---|
| What it is | Oral capsule containing Streptococcus salivarius 46-SL1 probiotic, given twice daily. | Placebo capsule designed to match the probiotic, taken twice daily. |
| Role in trial | Evaluated to reduce serum PFAS levels in previously exposed firefighters. | Serves as a control condition for direct comparison with the probiotic. |
| Primary use or purpose | Tested as a potential approach to lower blood levels of perfluorooctane sulfonic acid (PFOS) and related PFAS chemicals. | Used to measure the effects of the probiotic by comparison. |
| How it is given or performed | One probiotic capsule (~400mg) by mouth two times daily, with breakfast and evening meal, for 84 days per trial period. | One placebo capsule by mouth two times daily, with meals, for 84 days per trial period. |
| Evidence status | No results are yet available from this clinical trial. Recent preclinical and human microbiome research suggests certain gut bacteria can accumulate PFAS, but this probiotic's effect on reducing serum PFOS in humans remains unproven. | No effect expected on serum PFAS; serves as an inactive comparator to measure changes seen with the probiotic. |
| Important limitations | The effect of Streptococcus salivarius 46-SL1 in lowering PFOS or overall PFAS has not been confirmed in prior human studies. The trial population is limited to adult male firefighters with high PFOS exposure, which may limit generalizability. | Placebo contains inert substances and cannot improve or worsen PFAS levels. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants take either the probiotic supplement or placebo capsule twice daily for 12 weeks.
Multiple visits including baseline, day 42 call, and day 84 visit
Duration - 4 weeks
Participants stop taking study capsules for 4 weeks to clear previous treatment before switching.
Phone call on day 98
Duration - 12 weeks
Participants take the alternate capsule (probiotic or placebo) twice daily for 12 weeks.
Multiple visits including baseline, day 156 call, and day 196 visit
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Anna E Lindell, Anne Grießhammer, Lena Michaelis...
https://pubmed.ncbi.nlm.nih.gov/40595288/Cambiotics ApS
Lead Sponsor
Atlantia Food Clinical Trials
Collaborating Sponsor